News

12.01.20

Casma Therapeutics and Vipergen Enter Into Drug Discovery Agreement

READ MORE

11.17.20

Casma Therapeutics Appoints Nagesh Mahanthappa, Ph.D., MBA, to Board of Directors

READ MORE

09.10.20

Casma Therapeutics Announces $50 Million Series B Financing

READ MORE

01.13.20

Casma Therapeutics Appoints Two Experts in Lysosomal Proteostasis Pathways and Functional Genomics to Scientific Advisory Board

READ MORE

10.16.19

Casma Therapeutics Appoints Renowned Proteomic Specialist Steven Gygi to Scientific Advisory Board

READ MORE

09.23.19

Casma Therapeutics Named a 2019 “Fierce 15” Biotech Company

READ MORE

05.29.19

Casma Therapeutics Receives Grant from Michael J. Fox Foundation to Support Parkinson’s Drug Development

READ MORE

04.13.19

Casma Therapeutics Named one of the Boston Business Journal’s Best Places to Work

READ MORE

03.26.19

Casma Therapeutics Establishes Scientific Advisory Board with Appointments of Leading Autophagy and Neuroscience Researchers

READ MORE

12.12.18

Casma Therapeutics Strengthens Leadership Team with Appointment of Chief Operating Officer, Vice President of People & Culture

READ MORE

12.06.18

Casma Therapeutics Licenses Technology to Advance Autophagy-Based Drug Discovery

READ MORE

09.11.18

Casma Therapeutics Announces Partnership with Fondazione Telethon, Founder of the Telethon Institute of Genetics and Medicine (TIGEM)

READ MORE

08.06.18

Casma Therapeutics Expands Executive Team with Appointment of Two Senior Vice Presidents

READ MORE

05.30.18

Casma Therapeutics Co-Founder Reports Health Benefits of Increased Autophagy in Mammals in Nature Publication

READ MORE

05.03.18

Third Rock Ventures Launches Casma Therapeutics with $58.5 Million Investment to Harness the Cellular Process of Autophagy to Develop Breakthrough Therapies

READ MORE

Follow us on: